XML 111 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Narrative) (Details)			1 Months Ended	12 Months Ended
	Apr. 06, 2018 USD ($) milestone	Apr. 05, 2018 USD ($) option	Sep. 30, 2019 USD ($) performance_obligation material_right	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accounts receivable				$ 923,000	$ 3,678,000
Kite Pharma, Inc. | License
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract with customer liability		$ 150,000,000
Number of remaining performance obligations | performance_obligation			4
Number of material rights for renewal of research period | material_right			2
Renewal period			1 year
Fixed consideration			$ 150,000,000
Remaining performance obligation amount				0	19,700,000
Kite Pharma, Inc. | Collaboration and License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received	$ 150,000,000
Initial research term of agreement		6 years
Number of options to extend initial research term | option		2
Extended research term of agreement		1 year
Separate fee for additional term		$ 10,000,000
Contract with customer liability				0	19,400,000
Accounts receivable				200,000	$ 700,000
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development and sales-based milestone payments to be received	1,300,000,000
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development and sales-based milestone payments to be received	$ 1,800,000,000
Maximum amount of achieved milestones to receive payment | milestone	10
Kite Pharma, Inc. | Collaboration and License Agreement | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received	$ 3,000,000,000
Kite Pharma, Inc. | Collaborative Arrangement | Change in Agreement Estimate, March and September 2023
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Increase (decrease) in revenue				13,900,000
Increase (decrease) in net loss				$ 13,900,000
Increase (decrease) in basic net loss per share | $ / shares				$ 0.08
Increase (decrease) in diluted net loss per share | $ / shares				$ 0.08

X

- Definition

Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment

+ References

No definition available.

+ Details

Name:	sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Contingent development and sales based milestone payments to be received.

+ References

No definition available.

+ Details

Name:	sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Customer contract liability milestone payment eligible to receive.

+ References

No definition available.

+ Details

Name:	sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Extended Research Term Of Agreement

+ References

No definition available.

+ Details

Name:	sgmo_ExtendedResearchTermOfAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Increase (Decrease) In Earnings Per Share, Basic

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInEarningsPerShareBasic
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Increase (Decrease) In Earnings Per Share, Diluted

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInEarningsPerShareDiluted
Namespace Prefix:	sgmo_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Increase (Decrease) In Net Income (Loss) Attributable To Parent

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax

+ References

No definition available.

+ Details

Name:	sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Initial research term of agreement.

+ References

No definition available.

+ Details

Name:	sgmo_InitialResearchTermOfAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone payments received.

+ References

No definition available.

+ Details

Name:	sgmo_MilestonePaymentsReceived
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Number Of Options To Extend Initial Research Term

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfOptionsToExtendInitialResearchTerm
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue, Number Of Remaining Performance Obligations

+ References

No definition available.

+ Details

Name:	sgmo_RevenueNumberOfRemainingPerformanceObligations
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Revenue, Remaining Performance Obligation, Fixed Consideration Amount

+ References

No definition available.

+ Details

Name:	sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period

+ References

No definition available.

+ Details

Name:	sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Revenue, Remaining Performance Obligation, Renewal Period

+ References

No definition available.

+ Details

Name:	sgmo_RevenueRemainingPerformanceObligationRenewalPeriod
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Separate upfront fee.

+ References

No definition available.

+ Details

Name:	sgmo_SeparateUpfrontFee
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481990/310-10-45-9

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarchAndSeptember2023Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: